Researchers in Germany explored data from more than 400 TAVR patients, sharing their findings in the Journal of the American College of Cardiology. 

The global event, now in its second year, is raising money for Doctors Without Borders. 

The full analysis is scheduled to be presented May 16 at ACC.21.

Researchers emphasized the importance of these findings, noting that hypertension can lead to significant cardiovascular complications.

“What surprised me is that such small changes in electrolyte values have such dramatic effects,” one researcher said. 

The findings, published in the Journal of the American College of Cardiology, focused on data from the VIVID registry.

Dapagliflozin can help patients with CKD lower their risk of adverse renal and cardiovascular outcomes, the FDA said in a statement. 

The study's authors explored data from two different clinical trials, focusing on patients with HFrEF and HFpEF.

LDCT produced “remarkable” improvements in both behavior and cognition just days after treatment, according to a small study published in the Journal of Alzheimer's Disease.